4. Physiology
          4.4. Haematology
              4.4.1. Haemostasis
                  4.4.1.1. Clot formation
 4.4.1.1.3. Control of clot formation

A.2. Control of clot formation

Inhibitors of clot formation:

  1. Antithrombin III (AT3)
  2. Heparin cofactor II
  3. Thrombomodulin, Protein C and protein S
  4. Tissue factor inhibitor
  5. Endothelium
  6. Dilution

A.2.1. Antithrombin III (AT3)

[WG21:p546]

  • Circulating protease inhibitor that binds to serine proteases (e.g. thrombin and factor 10a)
    --> Blocking their activities
  • Accounts for 70% of plasma capacity to inhibit coagulation
    * 75% according to HH26
  • Produced by liver
  • Factors 9-12 are inhibited by AT3
    * [WG21:p546]
  • Thrombin and Factor 7/TF complex are also inhibited by AT3
    * [HH26:p603]
  • Binding is facilitated by heparin
    * Action is accelerated 1000 times by heparin
  • Hemoglobin also facilitates AT3 action
    * [WG21:p547] (but didn't elaborate on the mechanism)

A.2.2. Heparin cofactor II

  • Inhibits thrombin
  • Reaction greatly enhanced by heparin
  • Exact physiological role unclear

A.2.3. Thrombomodulin and protein C

All endothelial cells (except for those in cerebral microcirculation) produce thrombomodulin

Thrombomodulin binds to thrombin
--> Forms thrombomodulin-thrombin complex
--> Activates protein C

Activated protein C

[WG21:p546]

  • Protein S act as a co-factor
  • Activated by thrombomodulin-thrombin complex
  • Inactivates factor 5 and 8
  • Inactivates an inhibitor of tissue plasminogen activator (thus increasing plasmin formation)

A.2.4. Tissue factor inhibitor

(Referred to as tissue factor pathway inhibitor in WG21)

  • Synthesized by endothelium and also released by platelets
  • Binds factor 10a and inhibits Factor 7-TF complex
  • Main role: Removal of excessive Factor 10a

Extrinsic pathway is inhibited by a tissue factor pathway inhibitor that forms a quaternary structure with TPL, factor 7a and factor 10a

A.2.5. Role of endothelium in preventing clotting

  1. Anticoagulant surface (Heparan sulfate)
  2. Thrombomodulin
  3. Cell surface ADPase
    --> This enzyme metabolises ADP released from platelets
    * ADP otherwise would cause platelet aggregation
  4. Release prostacycline
    --> Inhibits platelet aggregation and a vasodilator
  5. Release NO
    --> Inhibits platelet aggregation and a vasodilator
  6. Production of tPA
    * Activates plasmin
    * Stimulated by local production of thrombin
  7. Production of prostacyclin
    * Synthesized by endothelium
    * Prevents platelet aggregation
    * Vasodilator
    * Also see Endothelium-related vasoactive substances

A.2.6 Dilution

Blood flow dilutes the level of active mediators and limits buildup



Table of contents  | Index